124 related articles for article (PubMed ID: 23858800)
1. [Extrahepatic manifestations of chronic hepatitis C and their influence on response to treatment with pegylated interferon alfa-2a and ribavirin].
Fabri M; Ruzić M; Lendak D; Preveden T; Fabri I; Petrić V
Srp Arh Celok Lek; 2013; 141(5-6):320-4. PubMed ID: 23858800
[TBL] [Abstract][Full Text] [Related]
2. [Efficacy and safety of peginterferon alfa-2a and ribavirin treatment of chronic hepatitis C in the Republic of Serbia].
Božić M; Bojović K; Fabri M; Nožić D; Trkulja B; Milošević I
Srp Arh Celok Lek; 2012; 140(7-8):448-55. PubMed ID: 23092029
[TBL] [Abstract][Full Text] [Related]
3. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial.
Manns M; Marcellin P; Poordad F; de Araujo ES; Buti M; Horsmans Y; Janczewska E; Villamil F; Scott J; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Sinha R; Beumont-Mauviel M
Lancet; 2014 Aug; 384(9941):414-26. PubMed ID: 24907224
[TBL] [Abstract][Full Text] [Related]
4. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial.
Jacobson IM; Dore GJ; Foster GR; Fried MW; Radu M; Rafalsky VV; Moroz L; Craxi A; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Scott J; Sinha R; Beumont-Mauviel M
Lancet; 2014 Aug; 384(9941):403-13. PubMed ID: 24907225
[TBL] [Abstract][Full Text] [Related]
5. Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection.
Ascione A; De Luca M; Tartaglione MT; Lampasi F; Di Costanzo GG; Lanza AG; Picciotto FP; Marino-Marsilia G; Fontanella L; Leandro G
Gastroenterology; 2010 Jan; 138(1):116-22. PubMed ID: 19852964
[TBL] [Abstract][Full Text] [Related]
6. Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonresponders.
Rustgi VK; Lee WM; Lawitz E; Gordon SC; Afdhal N; Poordad F; Bonkovsky HL; Bengtsson L; Chandorkar G; Harding M; McNair L; Aalyson M; Alam J; Kauffman R; Gharakhanian S; McHutchison JG;
Hepatology; 2009 Dec; 50(6):1719-26. PubMed ID: 19852040
[TBL] [Abstract][Full Text] [Related]
7. Enhanced efficacy of pegylated interferon alpha-2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomized trial and quality of life analysis.
Kamal SM; Ahmed A; Mahmoud S; Nabegh L; El Gohary I; Obadan I; Hafez T; Ghoraba D; Aziz AA; Metaoei M
Liver Int; 2011 Mar; 31(3):401-11. PubMed ID: 21281434
[TBL] [Abstract][Full Text] [Related]
8. Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study.
Escudero A; Rodríguez F; Serra MA; Del Olmo JA; Montes F; Rodrigo JM
J Gastroenterol Hepatol; 2008 Jun; 23(6):861-6. PubMed ID: 18422960
[TBL] [Abstract][Full Text] [Related]
9. Long-term pegylated interferon monotherapy following 72 weeks of pegylated interferon and ribavirin in hepatitis C virus genotype-1-infected slow responders.
Watanabe S; Kobayashi Y; Kawata K; Noritake H; Chida T; Nagasawa M; Kageyama F; Kawamura K; Sasada Y; Suda T
Intern Med; 2015; 54(3):273-9. PubMed ID: 25748735
[TBL] [Abstract][Full Text] [Related]
10. Effect of prolonged administration of pegylated interferon/ribavirin therapy in genotypes 2a and 2b: propensity score-matched analysis.
Yokoyama S; Kawakami Y; Imamura M; Hayes CN; Kohno H; Kohno H; Tsuji K; Aisaka Y; Kira S; Yamashina K; Nonaka M; Takahashi S; Moriya T; Kitamoto M; Aimitsu S; Nakanishi T; Kawakami H; Chayama K
J Gastroenterol Hepatol; 2015 Feb; 30(2):337-44. PubMed ID: 25091289
[TBL] [Abstract][Full Text] [Related]
11. Peginterferon alone or with ribavirin enhances HCV-specific CD4 T-helper 1 responses in patients with chronic hepatitis C.
Kamal SM; Fehr J; Roesler B; Peters T; Rasenack JW
Gastroenterology; 2002 Oct; 123(4):1070-83. PubMed ID: 12360469
[TBL] [Abstract][Full Text] [Related]
12. A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C.
Mangia A; Ricci GL; Persico M; Minerva N; Carretta V; Bacca D; Cela M; Piattelli M; Annese M; Maio G; Conte D; Guadagnino V; Pazienza V; Festi D; Spirito F; Andriulli A
J Viral Hepat; 2005 May; 12(3):292-9. PubMed ID: 15850470
[TBL] [Abstract][Full Text] [Related]
13. [Antiviral/immunomodulatory combination therapy: pegylated interferon alpha 2a and ribavirin in patients with chronic hepatitis C virus infection].
Delić D; Mitrović N; Popović N; Urošević A; Pešiċ I; Simonoviċ J
Srp Arh Celok Lek; 2012; 140(9-10):612-8. PubMed ID: 23289278
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of pegylated interferon alfa-2a or alfa-2b in combination with ribavirin in the treatment of chronic hepatitis caused by hepatitis C virus genotype 1b.
Mach TH; Cieśla A; Warunek W; Janas-Skulina U; Cibor D; Owczarek D; Ciećko-Michalska I
Pol Arch Med Wewn; 2011 Dec; 121(12):434-9. PubMed ID: 22157768
[TBL] [Abstract][Full Text] [Related]
15. Scientific rationale and study design of the individualized dosing efficacy vs flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: determining optimal dosing in patients with genotype 1 chronic hepatitis C.
McHutchison J; Sulkowski M
J Viral Hepat; 2008 Jul; 15(7):475-81. PubMed ID: 18363672
[TBL] [Abstract][Full Text] [Related]
16. [Comparison of therapeutic results between combination therapy of peginterferon alpha-2a plus ribavirin and interferon alpha-2b plus ribavirin according to treatment duration in patients with chronic hepatitis C].
Lee HJ; Eun JR; Choi JW; Kim KO; Moon HJ
Korean J Hepatol; 2008 Mar; 14(1):46-57. PubMed ID: 18367857
[TBL] [Abstract][Full Text] [Related]
17. [Efficacy and safety of pegylated interferon α-2b injection (Y shape, 40 kD) in treatment of patients with genotype 1/6 chronic hepatitis C].
Feng B; Shang J; Wu SH; Chen H; Han Y; Li YQ; Zhang DZ; Zhao LF; Wei SF; Mao Q; Yin CB; Han T; Wang MR; Chen SJ; Li J; Xie Q; Zhen Z; Gao ZL; Zhang YX; Gong GZ; Yang DL; Pan C; Sheng JF; Tang H; Ning Q; Shi GF; Niu JQ; Luo GH; Sun YT; You H; Wang GQ; Zhang LL; Peng J; Zhang Q; Liu JJ; Chen CW; Chen XY; Zhao W; Wang RH; Sun L; Wei L
Zhonghua Gan Zang Bing Za Zhi; 2017 Mar; 25(3):187-194. PubMed ID: 28482405
[No Abstract] [Full Text] [Related]
18. Response to pegylated interferon alfa-2a and ribavirin in chronic hepatitis C genotype 4.
El Makhzangy H; Esmat G; Said M; Elraziky M; Shouman S; Refai R; Rekacewicz C; Gad RR; Vignier N; Abdel-Hamid M; Zalata K; Bedossa P; Pol S; Fontanet A; Mohamed MK
J Med Virol; 2009 Sep; 81(9):1576-83. PubMed ID: 19626613
[TBL] [Abstract][Full Text] [Related]
19. Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients.
Laguno M; Cifuentes C; Murillas J; Veloso S; Larrousse M; Payeras A; Bonet L; Vidal F; Milinkovic A; Bassa A; Villalonga C; Pérez I; Tural C; Martínez-Rebollar M; Calvo M; Blanco JL; Martínez E; Sánchez-Tapias JM; Gatell JM; Mallolas J
Hepatology; 2009 Jan; 49(1):22-31. PubMed ID: 19085908
[TBL] [Abstract][Full Text] [Related]
20. Dual treatment with sofosbuvir plus ribavirin is as effective as triple therapy with pegylated interferon plus sofosbuvir plus ribavirin in predominant genotype 3 patients with chronic hepatitis C.
Satsangi S; Mehta M; Duseja A; Taneja S; Dhiman RK; Chawla Y
J Gastroenterol Hepatol; 2017 Apr; 32(4):859-863. PubMed ID: 27624314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
